Oral vs injectable peptide bioavailability — what the route actually changes

For most peptides, the honest answer is no. And the mechanism behind that answer is worth understanding, because it explains why the oral vs injectable distinction for this class of compounds is not a matter of preference — it's a matter of whether the compound reaches its target at all.

Peptides are chains of amino acids. They're also, from your gut's perspective, food. Your digestive system evolved over hundreds of millions of years to break down exactly this kind of structure — and it is extremely good at it. The moment a peptide enters your stomach, gastric acid begins denaturing its three-dimensional structure. Pepsin cleaves peptide bonds with efficiency. Anything that survives the stomach moves into the small intestine, where pancreatic enzymes — trypsin, chymotrypsin, elastase — continue the work. Brush border enzymes on the intestinal wall finish what the pancreatic enzymes started. The result, for most peptides, is that what arrives at the intestinal epithelium is not a peptide at all but a collection of individual amino acids and di- or tripeptides — metabolically useful, but pharmacologically inert relative to the original compound.

This is not a design flaw. It's your gut functioning precisely as intended. The problem is that it makes peptide drug delivery genuinely hard, and the solutions require specific chemistry that most consumer peptide products don't include.

There are exceptions, and they're worth naming precisely because understanding why they work as exceptions clarifies why everything else doesn't.

MK-677 is the most commonly cited oral option in the GH-axis space, and the crucial distinction is that it isn't actually a peptide. It's a non-peptide ghrelin mimetic — a small molecule that mimics the action of ghrelin at the growth hormone secretagogue receptor without being a peptide chain. Because it isn't a peptide, your digestive enzymes don't treat it as food. It has oral bioavailability in the range of 80% and a long half-life, which is precisely why it became the dominant oral option for people interested in GH secretagogue effects. The drug class name — secretagogue — applies to both MK-677 and peptides like sermorelin and ipamorelin, but the pharmacology of oral administration is entirely different. MK-677's oral viability is a function of its molecular identity, not a template for peptides generally.

BPC-157 occupies a more complicated position. It's a genuine peptide — fifteen amino acids derived from a protective protein found in gastric juice — and yet the original research on it was conducted using oral administration for gastric pathology. Rodent studies demonstrated healing effects on gastric ulcers when BPC-157 was administered orally, which suggested some degree of oral activity, at least in the gut itself. The mechanism proposed was a combination of local action at the gastric mucosa and a degree of stability that most peptides lack — BPC-157 appears to resist breakdown by gastric acid better than typical peptide structures. Whether that local stability translates into systemic bioavailability sufficient for the joint and systemic recovery effects that have drawn interest is a much less settled question. The preclinical data on oral BPC-157 for gastric conditions is more compelling than the data for oral BPC-157 for systemic effects, and the extrapolation from one to the other requires more evidence than currently exists. For systemic effects, injectable routes remain the pharmacologically better-supported approach.

The most serious engineering effort to solve oral peptide delivery is oral semaglutide — Rybelsus — which represents what it actually takes to get a clinically meaningful peptide through the gastrointestinal system. Novo Nordisk co-formulates semaglutide with SNAC: sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. SNAC is an absorption enhancer that works locally at the gastric mucosa by transiently disrupting the tight junctions between gastric epithelial cells, creating a brief window during which semaglutide can be absorbed before the cells reclose. The tablet must be taken on an empty stomach with a small amount of water, the patient must wait 30 minutes before eating or drinking, and even with all of that, the bioavailability of oral semaglutide is roughly 1% compared to subcutaneous injection — yet that 1% is enough to produce clinically meaningful GLP-1 receptor agonism when the dose is appropriately calibrated. Rybelsus reaches therapeutic effect with a 14 mg daily oral dose that is pharmacologically equivalent to a fraction of a weekly subcutaneous dose. This is the SNAC platform: a pharmaceutical technology that required years of development, specific formulation chemistry, and controlled clinical trials to establish that it works at the doses required. It is not a technology that consumer capsule products replicate.

The intranasal route opens a different path entirely. Semax and Selank, the Russian-developed cognitive peptides, are typically administered intranasally, and the logic is not simply that this bypasses the gut — it's that the olfactory pathway offers a relatively direct route toward central nervous system access. The nasal mucosa is richly vascularized and in close anatomical proximity to the brain; certain compounds absorbed at the olfactory epithelium travel via the olfactory nerve directly into the olfactory bulb and from there into central structures. This doesn't mean every intranasal peptide achieves meaningful CNS access — the pharmacokinetics are compound-specific — but for peptides with CNS targets, intranasal may be a genuinely better option than either oral or subcutaneous, not just a workaround. Oxytocin is another compound studied extensively via intranasal delivery, specifically because systemic oxytocin doesn't cross the blood-brain barrier efficiently but intranasal delivery allows bypass of that barrier for brain-targeted effects.

Topical delivery adds a third alternative for compounds with dermal targets. GHK-Cu, a copper-binding peptide researched for skin biology and wound healing, is commonly formulated into topical creams and serums. The evidence for topical GHK-Cu penetrating into the dermis where collagen-producing fibroblasts live is reasonable — the molecule is small enough and the skin is permeable enough — though the question of how much reaches fibroblasts at therapeutically relevant concentrations is not fully settled. Systemic bioavailability from topical GHK-Cu is likely minimal, which is appropriate when the target is the skin itself.

What this means practically is that the price comparison between oral and injectable versions of the same peptide needs to account for what you're actually buying. An oral capsule containing a peptide that is degraded before reaching the bloodstream is not a cheaper version of the injectable — it is a different product with a different (likely near-zero) systemic bioavailability. Paying 30% less for something with 5% of the exposure is not a bargain by any reasonable accounting. The relevant comparison is cost per unit of bioactive compound delivered to the target tissue, not cost per capsule.

This matters even more when the peptide in question has no documented mechanism that would explain oral stability. If a product description doesn't specify the delivery technology that explains how the compound survives gastric and enzymatic degradation, it's reasonable to ask — and to expect a specific technical answer, not a marketing claim. The SNAC platform works and its mechanism is documented. Enteric coating can bypass the stomach but doesn't address small intestinal protease activity. Liposomal formulations can improve absorption for some compounds. Each of these is a specific technology with specific evidence. "Enhanced bioavailability formula" is not.

The intranasal route for peptides like Semax and Selank, or SubQ for sermorelin, ipamorelin, BPC-157 in injectable form, TB-500, and most other research peptides, represents the route that aligns with the pharmacology of the compound. These aren't arbitrary preferences — they're a consequence of where the compound needs to go, how the body processes it, and what administration method the available evidence supports. Changing the route changes the compound's behavior in the body, and not always predictably.

Evaluating an oral peptide product critically means asking two questions before anything else: what is the mechanism by which this compound survives oral administration, and what evidence supports that mechanism for this specific compound at this specific dose? If the answers are vague, the product is likely delivering amino acids and di-peptides rather than pharmacologically active compound. That's not necessarily harmful. But it may not be what you're paying for, and that distinction is worth understanding before you decide the oral version is good enough.